About Us

LSK BioPartners, Inc (dba LSK BioPharma) is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco (and Pangyo, South Korea). LSK BioPharma (LSKB) specializes in clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two proprietary drug candidates; Apatinib, a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB holds worldwide rights for apatinib excluding China and has partnered with Bukwang Pharma for development and marketing in South Korea.

Meet Our People